Clinical Trials Logo

Staphylococcus Aureus clinical trials

View clinical trials related to Staphylococcus Aureus.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03263832 Active, not recruiting - Clinical trials for Staphylococcus Aureus

Evaluation of the Antibiofilmogramme Test During Orthopaedic Device-Related Infection

BJIBiofilm
Start date: June 1, 2015
Phase:
Study type: Observational [Patient Registry]

This is an observational study that does not change routine care. The primary objective of this study is to investigate the correlation between the administration of an antibiotherapy able to prevent biofilm formation according to the results of the Antibiofilmogramme test, and the relapse of the infection for patient with orthopaedic device-related infection.

NCT ID: NCT02572791 Active, not recruiting - Clinical trials for Staphylococcus Aureus

Staph Household Intervention for Eradication (SHINE)

SHINE
Start date: October 2015
Phase: Phase 4
Study type: Interventional

The investigators propose a pragmatic comparative effectiveness trial evaluating several decolonization strategies in patients with Staphylococcus aureus infection, their household contacts, and household environmental surfaces. The central hypothesis of this proposal is that an integrated approach of periodic personal and household environmental hygiene will reduce S. aureus transmission in households and subsequently decrease the incidence of skin and soft tissue infections (SSTI).

NCT ID: NCT01352936 Active, not recruiting - Bacteremia Clinical Trials

Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy

Start date: January 2011
Phase: N/A
Study type: Observational

Staphylococcus aureus, the most virulent of the many staphylococcal species, has been recognized as one of the most important and lethal human bacterial pathogens. With the increased incidence of methicillin-resistant staphylococcus aureus (MRSA) infection in community and hospitalized patients, MRSA infections are associated with greater lengths of stay, higher mortality, and increased costs. Vancomycin and teicoplanin, are the two most commonly used glycopeptides and are the first-choice of treatment for MRSA infection. Vancomycin-induced nephrotoxicity is still a point of controversy. Teicoplanin is not known to have any nephrotoxicity. Acute kidney injury is a common complication of critical illness, which is reported in 5 to 7% of hospitalized patients. It is associated with significantly increased mortality, length of stay, and costs across a broad spectrum of conditions.